Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils.
Radezolid (RX-1741) is the first biaryloxazolidinone in clinical development. It shows improved activity, including against linezolid-resistant strains. Radezolid differs from linezolid by the presence of a biaryl spacer and of a heteroaryl side chain, which increases the ionization and hydrophilicity of the molecule at physiological pH and confers to it a dibasic character. The aim of this study was to determine the accumulation and subcellular distribution of radezolid in phagocytic cells and to decipher the underlying mechanisms. In THP-1 human macrophages, J774 mouse macrophages, and human polymorphonuclear neutrophils, radezolid accumulated rapidly and reversibly (half-lives of approximately 6 min and 9 min for uptake and efflux, respectively) to reach, at equilibrium, a cellular concentration 11-fold higher than the extracellular one. This process was concentration and energy independent but pH dependent (accumulation was reduced to 20 to 30% of control values for cells in medium at a pH of <6 or in the presence of monensin, which collapses pH gradients between the extracellular and intracellular compartments). The accumulation at equilibrium was not affected by efflux pump inhibitors (verapamil and gemfibrozil) and was markedly reduced at 4 degrees C but was further increased in medium with low serum content. Subcellular fractionation studies demonstrated a dual subcellular distribution for radezolid, with approximately 60% of the drug colocalizing to the cytosol and approximately 40% to the lysosomes, with no specific association with mitochondria. These observations are compatible with a mechanism of transmembrane diffusion of the free fraction and partial segregation of radezolid in lysosomes by proton trapping, as previously described for macrolides.
Lemaire
Sandrine
S
Unité de Pharmacologie cellulaire et moléculaire, Université catholique de Louvain, Brussels, Belgium.
Tulkens
Paul M
PM
Van Bambeke
Françoise
F
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000493:pharmacokinetics*; D001693:Biological Transport, Active / Q000187:drug effects; D002460:Cell Line; D003470:Culture Media; D006207:Half-Life; D006801:Humans; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D007476:Ionophores / Q000494:pharmacology; D008264:Macrophages / Q000378:metabolism; D051379:Mice; D008985:Monensin / Q000494:pharmacology; D009504:Neutrophils / Q000378:metabolism; D023303:Oxazolidinones / Q000737:chemistry / Q000493:pharmacokinetics*; D010586:Phagocytes / Q000378:metabolism*; D011485:Protein Binding; D013696:Temperature
D000900:Anti-Bacterial Agents; D003470:Culture Media; D007476:Ionophores; D023303:Oxazolidinones; C552047:radezolid; D000255:Adenosine Triphosphate; D008985:Monensin
Bioorg Med Chem Lett. 2008 Dec 1;18(23):6175-8
18947996
Int J Pharm. 2001 Jun 19;221(1-2):219-26
11397583
J Antimicrob Chemother. 1990 Oct;26 Suppl B:27-39
2258352
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
11259830
Antimicrob Agents Chemother. 2009 Sep;53(9):3734-43
19564365
Antimicrob Agents Chemother. 2008 Oct;52(10):3550-7
18663023
J Infect Dis. 2005 Sep 15;192(6):1023-8
16107955
Eur J Cell Biol. 2001 Jul;80(7):466-78
11499789
Antimicrob Agents Chemother. 2010 Jun;54(6):2549-59
20385852
Trends Microbiol. 2000 Aug;8(8):341-3
10920387
Int J Tissue React. 1994;16(5-6):211-20
7558665
Cell. 1983 Apr;32(4):1026-8
6340834
Curr Opin Drug Discov Devel. 2006 Mar;9(2):218-30
16566292
Eur J Pharmacol. 1996 Oct 24;314(1-2):203-14
8957238
Antimicrob Agents Chemother. 2004 Jul;48(7):2673-82
15215125
Int J Cancer. 1980 Aug;26(2):171-6
6970727
Antimicrob Agents Chemother. 1990 Jun;34(6):1056-60
2168141
J Clin Pharmacol. 2002 Jun;42(6):620-43
12043951
Expert Opin Pharmacother. 2005 Oct;6(13):2315-26
16218891
Antimicrob Agents Chemother. 2003 Mar;47(3):1047-51
12604540
Antimicrob Agents Chemother. 2006 Mar;50(3):841-51
16495241
Antimicrob Agents Chemother. 1987 Mar;31(3):410-6
3579258
J Antimicrob Chemother. 2009 Nov;64(5):1035-43
19759040
Antimicrob Agents Chemother. 2006 Jul;50(7):2455-63
16801426
J Antimicrob Chemother. 2008 Jun;61(6):1288-94
18375379
Methods Mol Biol. 1998;79:179-83
9463833
Lab Invest. 1979 Apr;40(4):481-91
431047
J Antimicrob Chemother. 1987 Nov;20 Suppl B:47-56
3429386
Biochem Pharmacol. 1974 Sep 15;23(18):2495-531
4606365
Eur J Pharm Sci. 1998 Oct;6(4):317-24
9795088
Can J Infect Dis. 2001 Nov;12(6):379-90
18159365
J Antimicrob Chemother. 2003 Jun;51(6):1431-4
12746375
Am J Med. 1991 Sep 12;91(3A):5S-11S
1656743
J Infect Dis. 2004 Jun 1;189(11):2101-9
15143479
Biochem Pharmacol. 1978 Feb 15;27(4):415-24
24449
Physiol Rev. 1969 Apr;49(2):285-329
4889321
Antimicrob Agents Chemother. 2004 Aug;48(8):2853-60
15273091
Bioorg Med Chem Lett. 2008 Dec 1;18(23):6179-83
18951792
Curr Protoc Immunol. 2001 May;Chapter 3:3.20.1-3.20.6
18432785
Arch Intern Med. 1970 Aug;126(2):272-5
4914780
Curr Opin Microbiol. 2007 Oct;10(5):454-60
17928263
Cytotechnology. 1990 May;3(3):301-7
1366664
Antimicrob Agents Chemother. 2008 May;52(5):1653-62
18316525
Eur J Pharmacol. 1996 Oct 24;314(1-2):215-27
8957239
Antimicrob Agents Chemother. 2006 Jun;50(6):2042-9
16723564
Antimicrob Agents Chemother. 2007 Aug;51(8):2748-57
17548493
Antimicrob Agents Chemother. 2002 Dec;46(12):4013-5
12435714
J Cell Biol. 1976 Mar;68(3):665-87
1030706